← All trials
NCT05252988
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Oct 28, 2024
- Completion date
- Jan 31, 2030
- First posted
- Feb 23, 2022
- Last posted
- Nov 20, 2024
- Enrollment
- 315
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Spanish Breast Cancer Research GroupLead sponsor
- Hospital General Universitario Gregorio MarañonOfficial
- Pierre FabreCollaborator
- Puma Biotechnology, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.